David Baker’s Technology Transfer and Advisory Roles
Updated May 2023
David Baker is or was a co-founder, shareholder, or advisor to the following companies.
F = Founder/Co-Founder, A = Advisor
| Prospect Genomics | 1999 | F | A | Genomics and drug discovery; acquired by Eli Lilly/Structural GenomiX in 2001 | |
| Bio Architecture Lab | 2008 | A | Developing biofuels and renewable chemicals from macroalgae; no longer active, having licensed their technology to Statoil | ||
| Arzeda | 2009 | F | A | ACTIVE | Enzyme engineering for agribusiness and fine chemicals |
| Pregenen | 2011 | A | Engineering nucleases for genome engineering therapies; acquired in 2014 by Bluebird Bio | ||
| PVP Biologics | 2012 | F | A | Developing protein therapeutics for celiac disease; acquired by Takeda in 2020 | |
| Cue Biopharma | 2014 | A | Developing biologic immunotherapies | ||
| Cyrus Biotech | 2014 | F | A | ACTIVE | Cloud-based software for biomolecular design |
| Virvio | 2017 | A | Developing broadly-protective influenza therapeutics | ||
| Icosavax | 2018 | F | A | ACTIVE | Developing protein nanoparticle vaccines for respiratory viruses |
| A-Alpha Bio | 2018 | F | A | ACTIVE | Accelerating target discovery, library screening, and preclinical drug characterization |
| Neoleukin Therapeutics | 2018 | F | A | ACTIVE | Developing proteins that activate the immune system to fight cancer |
| Sana Biotechnology | 2019 | F | A | ACTIVE | Creating and delivering engineered cells as medicine for patients |
| Lyell Immunotherapeutics | 2019 | F | A | ACTIVE | Developing T-cells to eliminate solid cancers |
| Mopac Biologics | 2020 | A | ACTIVE | Developing protein therapeutics for gastrointesinal inflammation diseases | |
| Monod Bio | 2021 | A | ACTIVE | Developing protein biosensors for diagnostic applications | |
| Brahma | 2021 | A | ACTIVE | Designing bi-specific protein therapeutics | |
| Charm | 2021 | A | ACTIVE | Applying machine learning to small molecule drug discovery | |
| Transycton Bio | 2021 | A | ACTIVE | Developing blood-brain barrier traversal agents | |
| Nighthawk | 2022 | A | ACTIVE | ||
| Axxis | 2022 | A | ACTIVE | ||
| Developing protein therapeutics for gastrointestinal inflammation diseases | 2022 | A | ACTIVE | Designing protein nanomaterials for regenerative medicine and cancer | |
| Lila | 2022 | A | ACTIVE | Developing treatments for fibrotic diseases | |
| Vilya | 2023 | A | ACTIVE | Developing permeable drug molecules to target traditionally un-druggable targets |
Rosetta Licensing is managed by UW CoMotion. Royalty proceeds are managed by the Rosetta Commons. Rosetta software has been licensed to numerous non-profit and for-profit organizations.